A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Given the evidence that coordinate inhibition of AKT induces autophagy, we studied the combination of the AKT inhibitor, MK-2206 with hydroxychloroquine (HCQ) in patients with advanced solid tumors.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Chemother Pharmacol

Title: Cancer chemotherapy and pharmacology

Publisher: Springer Science and Business Media LLC

ISSN (Electronic): 1432-0843

ISSN (Print): 0344-5704

Publication date (Electronic): October 2019

Volume: 84

Issue: 4

Affiliations

[1 ] Rutgers Cancer Institute of New Jersey, The State University of New Jersey, 195 Little Albany Street, New Brunswick, NJ, USA. mehnerja@rutgers.cinj.edu.

[2 ] Rutgers Cancer Institute of New Jersey, The State University of New Jersey, 195 Little Albany Street, New Brunswick, NJ, USA.

[3 ] National Cancer Institute-Cancer Therapy Evaluation Program, Bethesda, MD, USA.

Article

Publisher Item ID: 10.1007/s00280-019-03919-x

DOI: 10.1007/s00280-019-03919-x

PubMed ID: 31463691

SO-VID: b70688df-4161-4b1a-9fd6-1f2de5ba8037

History

Keywords: AKT,Autophagy,Hydroxychloroquine,MK-2206,Phase I

Data availability:

Keywords: AKT, Autophagy, Hydroxychloroquine, MK-2206, Phase I

Comments

Comment on this article

scite_

Cited by 11

See all cited by